GBA Presents: RADIO SAVANT-!

H&M-

Company Profile
H & M Hennes & Mauritz AB (publ) provides clothing, accessories, footwear, cosmetics, home textiles, and homeware for women, men, teenagers, children, and babies worldwide. It offers sportswear, shoes, bags, beauty products, and ready-to-wear; and interior products, including bed linens, dinnerware, textiles, furniture, and lighting. The company provides its products under the H&M, H&M HOME, COS, & Other Stories, Monki, Weekday, ARKET, Afound, Singular Society, Treadler, Creator Studio, and Sellpy brands. H & M Hennes & Mauritz AB (publ) was founded in 1947 and is headquartered in Stockholm, Sweden.

Earn were yest-


$2.71 0.41(+17.83%)1
 
Normally a small oil & gas outfit would not catch my attention. Gas being less thought of now...
but I looked at a financial statement and I see a real ramp up here--

Total Rev $15.9 mil in 2021

Total rev $30 mil in 2022

It doesn't take a genius to see that's growing 100%

PED PEDEVCO Corp.
$0.950.09(+9.83%)11:59 AM 03/30/23

NYSE |$USD |Pre-Market:$1.04+0.09(+9.47%)<-------------
 
Company Profile
BRZE

Braze, Inc. operates a customer engagement platform that provides interactions between consumers and brands worldwide. It offers data ingestion products, such as Braze software development kits that automatically manage data ingestion and the delivery of mobile and web notifications, in-application/in-browser interstitial messages, and content cards, as well as can be integrated into a range of digital interfaces and application development frameworks; REST API that can be used to import or export data or to trigger workflows between Braze and brands’ existing technology stacks; and partner cohort syncing, which allow brands to sync user cohorts from partners. The company also offers classification products, including segmentation that can define reusable segments of consumers based upon attributes, events, or predictive propensity scores; segment insights, which allows customers to analyze how segments are performing relative to each other across a set of pre-selected key performance indicators, and helps to understand the factors that determine which consumers belong to a particular segment; and predictive suite that allows customers to identify groups of consumers that are of critical business value. In addition, it provides personalization and action products; and orchestration products, which include Canvas, an orchestration tool that allows customers to create journeys, mapping out multi-steps, and cross-channel messaging experiences, which include onboarding flows, nurture campaigns, win-back strategies, and others; campaigns, which allow customers to send one set of single-channel or multi-channel messages to be delivered to customers in a particular user segment; event and API triggering; frequency capping and rate limiting; intelligent selection; and reporting and analytics. The company was formerly known as Appboy, Inc. and changed its name to Braze, Inc. in November 2017. Braze, Inc. was incorporated in 2011 and is headquartered in New York, New York.

 
SPERO

As is the case with alot of Bios I have a history here- For years I held SPRO until I could not take it anymore.

I have always thought new drugs for bacterial infections was very important and back when Flesh Eating Disease was the rage I was all over this name that never rewarded me...

They seem to have narrowed their focus to UTI's>

Spero Therapeutics, a clinical-stage biopharmaceutical company, is committed to combating the increasing threat of MDR bacterial infections by investing in the development of transformative antibiotics to fight cUTI and other rare diseases.

Complicated Urinary Tract Infections (cUTIs) can be debilitating to patients and are a high burden on health care professionals and the healthcare system. Their frequency of recurrence often leads to chronic pain and bladder dysfunction, and in some cases, potential life-threatening complications. Increased treatment failures and recurrence are consequences of the increasing rates of difficult to treat ESBL infections and Multiple Drug Resistance (MDR), leaving patients and health care professionals fewer treatment options. Resistance limitations on appropriate antibiotic selection in the treatment of cUTI are further compounded by other intrinsic drug-related factors such as bioavailability and tissue penetration. For these reasons, and despite a number of oral and IV available options to treat c-UTI, there is a real and present unmet need for patients with cUTIs.

Spero are developing an investigational oral carbapenem to address the current unmet need in the treatment of cUTI across multiple settings of care. Through intricate collaboration across scientific disciplines, Spero’s team and collaborators are able to effectively identify a promising molecule and turn it into a medicine that can safely and effectively address the needs of patients.



SPRO Spero Therapeutics, Inc.


$1.44-0.01(-0.69%)11:59 AM 03/30/23

NASDAQ |$USD |Pre-Market:$1.61+0.17(+11.81%)<---------------
 
Last QTR SPRO lost (33c)

This Qtr--> they Made 55c!but lost money-?

Spero Therapeutics reports Q4 EPS 55c, consensus 4c 16:19 SPRO Reports Q4 revenue $47.4M, consensus $22.87M."We were pleased to recently initiate our Phase 2 trial of Spero reported net income of $26.8M for the fourth quarter and an overall net loss of $46.4M, for the year ended December 31 , or a net income of 55c and net loss of $1.23 per share of common stock, respectively. Net loss for the fourth quarter and year ended December 31, 2021, was $29.2 million and $89.8 million, or 90c and $2.91 per share of common stock, respectively.SPR720 in NTM-PD," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. "A key objective of the trial is to provide clinical proof-of-concept for SPR720 by demonstrating its ability to drive microbiological response against NTM as a single agent versus placebo. We believe achieving clinical proof of concept would substantially de-risk SPR720 and further demonstrate its potential to address the pressing unmet need for an effective, durable, and tolerable first-line therapy for patients with NTM-PD."Dr. Mahadevia continued, "We were also delighted to close our exclusive license agreement with GSK for tebipenem HBr last quarter, adding strength to our balance sheet and shareholder base with a $66 million upfront payment, a $9 million equity investment, and potentially significant, near and long-term milestones and royalties. We believe our collaboration with GSK will help position tebipenem HBr to be the first potential oral treatment for complicated urinary tract infections. We also remain on track to advance SPR206 into an externally funded Phase 2 trial in patients with either hospital-acquired or ventilator-associated bacterial pneumonia, with an expectation to file the IND, later this year. This further demonstrates our ability to leverage creative partnerships to advance our multi-asset pipeline with a capital-efficient approach."

<Ok if these guys can get their act together..... GSK will buy them.>
 
You must log in or register to reply here.
Back
Top